Antitumour activity of oleanolic acid: A systematic review and meta‑analysis
Oleanolic acid (OA), a compound known for its potent antitumour properties, has been the subject of investigations in both cell and animal models. Although OA has good biological activity, its low water solubility and bioavailability limit its therapeutic use, and therefore translating the potential...
Saved in:
| Published in | Oncology letters Vol. 28; no. 6; p. 582 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Greece
Spandidos Publications
01.12.2024
Spandidos Publications UK Ltd D.A. Spandidos |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1792-1074 1792-1082 |
| DOI | 10.3892/ol.2024.14715 |
Cover
Loading…
| Abstract | Oleanolic acid (OA), a compound known for its potent antitumour properties, has been the subject of investigations in both cell and animal models. Although OA has good biological activity, its low water solubility and bioavailability limit its therapeutic use, and therefore translating the potential of OA into the clinical oncology setting remains challenging. The present systematic review and meta-analysis utilized evidence from animal model studies to gain insights into the antitumour mechanisms of OA to address the gap in understanding, and to provide guidance for future research directions and potential clinical applications. The guidelines outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses were applied in the present study and a comprehensive search was conducted across the PubMed/MEDLINE, Web of Science, Cochrane Library and Embase databases, with a cut-off date of June 30, 2023. The primary focus was on randomized controlled trials that used animal models to assess the antitumour effects of OA. The methodological quality appraisal was conducted using the Systematic Review Centre for Laboratory Animal Experimentation risk of bias tool, and tumour volume and weight served as the principal outcome measures. Data were analysed using the RevMan (version 5.3) and Stata SE11 software packages, with an assessment of heterogeneity conducted using the I
statistical test, sensitivity analysis conducted using the leave-one-out approach, and evaluation of publication bias performed using Egger's test and funnel plot analysis. The present study demonstrated a significant inhibitory effect of OA intervention on tumour growth and a decrease in tumour weight in animal models. Despite the broad spectrum of antitumour effects exhibited by OA, further investigations are warranted to optimize the dosage and administration routes of OA to maximize its efficacy in clinical cancer treatment. |
|---|---|
| AbstractList | Oleanolic acid (OA), a compound known for its potent antitumour properties, has been the subject of investigations in both cell and animal models. Although OA has good biological activity, its low water solubility and bioavailability limit its therapeutic use, and therefore translating the potential of OA into the clinical oncology setting remains challenging. The present systematic review and meta-analysis utilized evidence from animal model studies to gain insights into the antitumour mechanisms of OA to address the gap in understanding, and to provide guidance for future research directions and potential clinical applications. The guidelines outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses were applied in the present study and a comprehensive search was conducted across the PubMed/MEDLINE, Web of Science, Cochrane Library and Embase databases, with a cut-off date of June 30, 2023. The primary focus was on randomized controlled trials that used animal models to assess the antitumour effects of OA. The methodological quality appraisal was conducted using the Systematic Review Centre for Laboratory Animal Experimentation risk of bias tool, and tumour volume and weight served as the principal outcome measures. Data were analysed using the RevMan (version 5.3) and Stata SE11 software packages, with an assessment of heterogeneity conducted using the I
statistical test, sensitivity analysis conducted using the leave-one-out approach, and evaluation of publication bias performed using Egger's test and funnel plot analysis. The present study demonstrated a significant inhibitory effect of OA intervention on tumour growth and a decrease in tumour weight in animal models. Despite the broad spectrum of antitumour effects exhibited by OA, further investigations are warranted to optimize the dosage and administration routes of OA to maximize its efficacy in clinical cancer treatment. Oleanolic acid (OA), a compound known for its potent antitumour properties, has been the subject of investigations in both cell and animal models. Although OA has good biological activity, its low water solubility and bioavailability limit its therapeutic use, and therefore translating the potential of OA into the clinical oncology setting remains challenging. The present systematic review and meta-analysis utilized evidence from animal model studies to gain insights into the antitumour mechanisms of OA to address the gap in understanding, and to provide guidance for future research directions and potential clinical applications. The guidelines outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses were applied in the present study and a comprehensive search was conducted across the PubMed/MEDLINE, Web of Science, Cochrane Library and Embase databases, with a cut-off date of June 30, 2023. The primary focus was on randomized controlled trials that used animal models to assess the antitumour effects of OA. The methodological quality appraisal was conducted using the Systematic Review Centre for Laboratory Animal Experimentation risk of bias tool, and tumour volume and weight served as the principal outcome measures. Data were analysed using the RevMan (version 5.3) and Stata SE11 software packages, with an assessment of heterogeneity conducted using the [I.sup.2] statistical test, sensitivity analysis conducted using the leave-one-out approach, and evaluation of publication bias performed using Egger's test and funnel plot analysis. The present study demonstrated a significant inhibitory effect of OA intervention on tumour growth and a decrease in tumour weight in animal models. Despite the broad spectrum of antitumour effects exhibited by OA, further investigations are warranted to optimize the dosage and administration routes of OA to maximize its efficacy in clinical cancer treatment. Key words: oleanolic acid, biological products, pentacyclic triterpenes, neoplasms, animal tumour model, meta-analysis Oleanolic acid (OA), a compound known for its potent antitumour properties, has been the subject of investigations in both cell and animal models. Although OA has good biological activity, its low water solubility and bioavailability limit its therapeutic use, and therefore translating the potential of OA into the clinical oncology setting remains challenging. The present systematic review and meta-analysis utilized evidence from animal model studies to gain insights into the antitumour mechanisms of OA to address the gap in understanding, and to provide guidance for future research directions and potential clinical applications. The guidelines outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses were applied in the present study and a comprehensive search was conducted across the PubMed/MEDLINE, Web of Science, Cochrane Library and Embase databases, with a cut-off date of June 30, 2023. The primary focus was on randomized controlled trials that used animal models to assess the antitumour effects of OA. The methodological quality appraisal was conducted using the Systematic Review Centre for Laboratory Animal Experimentation risk of bias tool, and tumour volume and weight served as the principal outcome measures. Data were analysed using the RevMan (version 5.3) and Stata SE11 software packages, with an assessment of heterogeneity conducted using the I 2 statistical test, sensitivity analysis conducted using the leave-one-out approach, and evaluation of publication bias performed using Egger's test and funnel plot analysis. The present study demonstrated a significant inhibitory effect of OA intervention on tumour growth and a decrease in tumour weight in animal models. Despite the broad spectrum of antitumour effects exhibited by OA, further investigations are warranted to optimize the dosage and administration routes of OA to maximize its efficacy in clinical cancer treatment. Oleanolic acid (OA), a compound known for its potent antitumour properties, has been the subject of investigations in both cell and animal models. Although OA has good biological activity, its low water solubility and bioavailability limit its therapeutic use, and therefore translating the potential of OA into the clinical oncology setting remains challenging. The present systematic review and meta-analysis utilized evidence from animal model studies to gain insights into the antitumour mechanisms of OA to address the gap in understanding, and to provide guidance for future research directions and potential clinical applications. The guidelines outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses were applied in the present study and a comprehensive search was conducted across the PubMed/MEDLINE, Web of Science, Cochrane Library and Embase databases, with a cut-off date of June 30, 2023. The primary focus was on randomized controlled trials that used animal models to assess the antitumour effects of OA. The methodological quality appraisal was conducted using the Systematic Review Centre for Laboratory Animal Experimentation risk of bias tool, and tumour volume and weight served as the principal outcome measures. Data were analysed using the RevMan (version 5.3) and Stata SE11 software packages, with an assessment of heterogeneity conducted using the I2 statistical test, sensitivity analysis conducted using the leave-one-out approach, and evaluation of publication bias performed using Egger's test and funnel plot analysis. The present study demonstrated a significant inhibitory effect of OA intervention on tumour growth and a decrease in tumour weight in animal models. Despite the broad spectrum of antitumour effects exhibited by OA, further investigations are warranted to optimize the dosage and administration routes of OA to maximize its efficacy in clinical cancer treatment. Oleanolic acid (OA), a compound known for its potent antitumour properties, has been the subject of investigations in both cell and animal models. Although OA has good biological activity, its low water solubility and bioavailability limit its therapeutic use, and therefore translating the potential of OA into the clinical oncology setting remains challenging. The present systematic review and meta-analysis utilized evidence from animal model studies to gain insights into the antitumour mechanisms of OA to address the gap in understanding, and to provide guidance for future research directions and potential clinical applications. The guidelines outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses were applied in the present study and a comprehensive search was conducted across the PubMed/MEDLINE, Web of Science, Cochrane Library and Embase databases, with a cut-off date of June 30, 2023. The primary focus was on randomized controlled trials that used animal models to assess the antitumour effects of OA. The methodological quality appraisal was conducted using the Systematic Review Centre for Laboratory Animal Experimentation risk of bias tool, and tumour volume and weight served as the principal outcome measures. Data were analysed using the RevMan (version 5.3) and Stata SE11 software packages, with an assessment of heterogeneity conducted using the [I.sup.2] statistical test, sensitivity analysis conducted using the leave-one-out approach, and evaluation of publication bias performed using Egger's test and funnel plot analysis. The present study demonstrated a significant inhibitory effect of OA intervention on tumour growth and a decrease in tumour weight in animal models. Despite the broad spectrum of antitumour effects exhibited by OA, further investigations are warranted to optimize the dosage and administration routes of OA to maximize its efficacy in clinical cancer treatment. |
| ArticleNumber | 582 |
| Audience | Academic |
| Author | Wang, Zhonglian Zhang, Jing Jian, Wei Fu, Qiaofen Zeng, Ying |
| AuthorAffiliation | Department of Radiation Oncology, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650032, P.R. China |
| AuthorAffiliation_xml | – name: Department of Radiation Oncology, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650032, P.R. China |
| Author_xml | – sequence: 1 givenname: Ying surname: Zeng fullname: Zeng, Ying organization: Department of Radiation Oncology, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650032, P.R. China – sequence: 2 givenname: Zhonglian surname: Wang fullname: Wang, Zhonglian organization: Department of Radiation Oncology, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650032, P.R. China – sequence: 3 givenname: Jing surname: Zhang fullname: Zhang, Jing organization: Department of Radiation Oncology, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650032, P.R. China – sequence: 4 givenname: Wei surname: Jian fullname: Jian, Wei organization: Department of Radiation Oncology, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650032, P.R. China – sequence: 5 givenname: Qiaofen surname: Fu fullname: Fu, Qiaofen organization: Department of Radiation Oncology, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650032, P.R. China |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39421313$$D View this record in MEDLINE/PubMed |
| BookMark | eNptks1O3DAUha0KVChl2W0VqRK7DP5LbHdTjRCllRDd0LXlcW4YI8emsTNodrwCr9gnqfkbGKn2wtb1d490fM8HtBNiAIQ-ETxjUtHj6GcUUz4jXJDmHdonQtGaYEl3NnfB99BhSte4rKYlUrbv0R5TnBJG2D66mIfs8jTEaayMzW7l8rqKfRU9mBC9s6Xquq_VvErrlGEwuZRGWDm4rUzoqgGy-Xt3b4Lx6-TSR7TbG5_g8Pk8QL-_n16e_KjPf539PJmf15YLnGsGRjSMAcG4a-kCVK8sw0BsTxusFF60ynAlLLWqB9mxrqFCCLMwXDYADLMD9O1J92ZaDNBZCHk0Xt-MbjDjWkfj9PZLcEt9FVeaEC45UU1R-PKsMMY_E6Ssr8sfFBtJM0JbyXFL2Ct1ZTxoF_pY1OzgktVzSYRosZSiULP_UGV3MDhbRta7Ut9qOHrTsATj8zJFP2UXQ9oGP7_1uTH4MsAC1E-AHWNKI_QbhGD9kBEdvX7IiH7MCPsHGY-tRw |
| Cites_doi | 10.1016/j.jcyt.2021.10.010 10.1021/jm301910a 10.1002/jat.2725 10.3892/mmr.2016.5171 10.1111/j.2042-7158.1992.tb03646.x 10.1002/cbin.10612 10.1002/smll.202205531 10.1002/jbt.22621 10.1038/s41389-022-00420-8 10.3390/ijms18030643 10.1111/nyas.13387 10.1007/s13277-015-4655-9 10.4238/gmr.15028642 10.3390/pharmaceutics14051108 10.7314/APJCP.2014.15.11.4519 10.1016/j.cbi.2021.109619 10.3892/ijo.2015.3198 10.1016/j.phytochem.2017.11.013 10.1016/j.critrevonc.2022.103751 10.1016/j.ijpharm.2016.11.056 10.1016/j.jff.2021.104854 10.3390/ijms20163849 10.1016/j.bbrc.2021.01.028 10.3390/cancers14122938 10.1016/j.biopha.2016.11.091 10.1021/acs.jnatprod.5b01055 10.1088/0957-4484/24/23/235102 10.1016/j.ejmech.2018.12.046 10.1016/j.cbi.2022.110010 10.2147/DDDT.S84448 10.1080/14756360701633187 10.1016/j.jep.2005.05.024 10.1371/journal.pone.0072079 10.1016/j.ajps.2016.06.006 10.1124/mol.117.109900 10.2174/092986713805219082 10.1002/mc.22810 10.7326/ACPJC-1995-123-3-A12 10.1016/j.febslet.2008.03.026 10.3389/fphar.2020.00747 10.1002/mnfr.200600113 10.1021/jf500622p 10.3389/fphar.2016.00202 10.2174/1574892818666230417093208 10.1016/j.jneumeth.2013.09.010 10.1002/med.10053 10.1016/j.ejpb.2015.11.013 10.3390/molecules26164957 10.3892/or.2012.1921 10.1136/bmj.n160 10.1016/j.bmcl.2014.07.055 10.1186/1471-2288-14-43 10.21037/tcr-21-1733 10.3390/ijms22084180 10.1016/j.gene.2019.143956 10.6023/cjoc201207019 10.18632/aging.203582 10.1186/s40364-020-00212-5 10.1007/s11010-014-2228-7 10.18632/oncotarget.25316 10.3322/caac.21660 10.7150/ijms.3635 10.2174/1871520617666171020124916 10.1007/s12272-014-0345-1 10.2147/DDDT.S133997 10.1080/01635581.2020.1776887 10.1002/jor.21311 10.1136/bmj.n71 10.1155/2022/5887671 10.1097/CAD.0000000000000777 10.1002/ptr.7538 10.1158/1535-7163.MCT-18-0448 10.1093/carcin/bgt058 10.1016/j.cbi.2019.03.029 10.3390/ijms22179451 10.1016/j.biopha.2021.112397 10.1016/j.bcp.2009.08.002 |
| ContentType | Journal Article |
| Copyright | Copyright: © 2024 Zeng et al. COPYRIGHT 2024 Spandidos Publications Copyright Spandidos Publications UK Ltd. 2024 Copyright: © 2024 Zeng et al. 2024 |
| Copyright_xml | – notice: Copyright: © 2024 Zeng et al. – notice: COPYRIGHT 2024 Spandidos Publications – notice: Copyright Spandidos Publications UK Ltd. 2024 – notice: Copyright: © 2024 Zeng et al. 2024 |
| DBID | AAYXX CITATION NPM 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AN0 BENPR CCPQU FYUFA GHDGH K9. M0S PHGZM PHGZT PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 5PM |
| DOI | 10.3892/ol.2024.14715 |
| DatabaseName | CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland British Nursing Database (Proquest) ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) ProQuest Central Premium ProQuest One Academic ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) British Nursing Index with Full Text ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection ProQuest One Health & Nursing Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central (New) ProQuest One Academic ProQuest Central (Alumni) ProQuest One Academic (New) |
| DatabaseTitleList | PubMed ProQuest One Academic Middle East (New) |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X7 name: Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1792-1082 |
| ExternalDocumentID | PMC11484195 A817760887 39421313 10_3892_ol_2024_14715 |
| Genre | Journal Article |
| GeographicLocations | China United States--US Netherlands |
| GeographicLocations_xml | – name: China – name: Netherlands – name: United States--US |
| GrantInformation_xml | – fundername: National Natural Science Foundation of China grantid: 82160529 – fundername: 535 Talent Project of the First Affiliated Hospital of Kunming Medical University grantid: 2023535D17 – fundername: Applied Basic Science Research Foundation of Yunnan Province grantid: 202201AT070294 – fundername: Yunnan Revitalization Talent Support Program grantid: RLQB20220014 |
| GroupedDBID | --- 0R~ 53G 7X7 8FI 8FJ AAKDD AAYXX ABDBF ABJNI ABUWG ACGFS ACUHS ADBBV AENEX AFKRA AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AN0 BENPR BNQBC BPHCQ BVXVI C45 CCPQU CITATION EBD EBS EJD ESX F5P FYUFA HMCUK HUR HZ~ IAO IHR IHW IPNFZ ITC O9- OK1 OVD PHGZM PHGZT PQQKQ PROAC RIG RPM TEORI UKHRP W2D NPM PMFND 3V. 7XB 8FK K9. PKEHL PPXIY PQEST PQUKI PRINS 5PM |
| ID | FETCH-LOGICAL-c470t-3ea7533e100d62be9f9c30e1cf250990b69a497c2c9fe8d3d52777aba485ee303 |
| IEDL.DBID | 7X7 |
| ISSN | 1792-1074 |
| IngestDate | Thu Aug 21 18:31:26 EDT 2025 Fri Jul 25 22:26:23 EDT 2025 Tue Jun 17 22:03:56 EDT 2025 Tue Jun 10 21:06:54 EDT 2025 Thu May 22 21:23:36 EDT 2025 Thu Jan 02 22:31:25 EST 2025 Tue Jul 01 01:59:12 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 6 |
| Keywords | pentacyclic triterpenes meta-analysis animal tumour model neoplasms oleanolic acid biological products |
| Language | English |
| License | Copyright: © 2024 Zeng et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c470t-3ea7533e100d62be9f9c30e1cf250990b69a497c2c9fe8d3d52777aba485ee303 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 Contributed equally |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC11484195 |
| PMID | 39421313 |
| PQID | 3126840613 |
| PQPubID | 2044954 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_11484195 proquest_journals_3126840613 gale_infotracmisc_A817760887 gale_infotracacademiconefile_A817760887 gale_healthsolutions_A817760887 pubmed_primary_39421313 crossref_primary_10_3892_ol_2024_14715 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-12-01 |
| PublicationDateYYYYMMDD | 2024-12-01 |
| PublicationDate_xml | – month: 12 year: 2024 text: 2024-12-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Greece |
| PublicationPlace_xml | – name: Greece – name: Athens |
| PublicationTitle | Oncology letters |
| PublicationTitleAlternate | Oncol Lett |
| PublicationYear | 2024 |
| Publisher | Spandidos Publications Spandidos Publications UK Ltd D.A. Spandidos |
| Publisher_xml | – name: Spandidos Publications – name: Spandidos Publications UK Ltd – name: D.A. Spandidos |
| References | Lu (key20241112101859_b41-ol-28-6-14715) 2021; 35 Yang (key20241112101859_b70-ol-28-6-14715) 2013; 8 Lee (key20241112101859_b63-ol-28-6-14715) 2021; 87 Woo (key20241112101859_b65-ol-28-6-14715) 2021; 347 Hosny (key20241112101859_b44-ol-28-6-14715) 2021; 73 Richardson (key20241112101859_b56-ol-28-6-14715) 1995; 123 Zhong (key20241112101859_b69-ol-28-6-14715) 2019; 164 Ramos (key20241112101859_b8-ol-28-6-14715) 2021; 22 Xia (key20241112101859_b74-ol-28-6-14715) 2017; 11 Cichewicz (key20241112101859_b23-ol-28-6-14715) 2004; 24 Mu (key20241112101859_b26-ol-28-6-14715) 2015; 8 Guo (key20241112101859_b29-ol-28-6-14715) 2013; 8 Ren (key20241112101859_b43-ol-28-6-14715) 2024; 19 Gao (key20241112101859_b64-ol-28-6-14715) 2016; 15 Sun (key20241112101859_b82-ol-28-6-14715) 2020; 8 Zhou (key20241112101859_b28-ol-28-6-14715) 2011; 29 Tang (key20241112101859_b45-ol-28-6-14715) 2022; 145 Žiberna (key20241112101859_b68-ol-28-6-14715) 2017; 18 Nie (key20241112101859_b66-ol-28-6-14715) 2016; 40 Maganti (key20241112101859_b80-ol-28-6-14715) 2022; 24 Hung (key20241112101859_b4-ol-28-6-14715) 2019; 20 Li (key20241112101859_b38-ol-28-6-14715) 2019; 712 Page (key20241112101859_b54-ol-28-6-14715) 2021; 372 Vesterinen (key20241112101859_b60-ol-28-6-14715) 2014; 221 Xu (key20241112101859_b36-ol-28-6-14715) 2018; 57 Li (key20241112101859_b35-ol-28-6-14715) 2016; 37 Luo (key20241112101859_b83-ol-28-6-14715) 2023; 19 Jiang (key20241112101859_b72-ol-28-6-14715) 2016; 99 Niu (key20241112101859_b62-ol-28-6-14715) 2018; 18 Vasseur (key20241112101859_b9-ol-28-6-14715) 2022; 11 Wei (key20241112101859_b75-ol-28-6-14715) 2022; 14 Baskar (key20241112101859_b6-ol-28-6-14715) 2012; 9 Liu (key20241112101859_b33-ol-28-6-14715) 2014; 15 Gao (key20241112101859_b5-ol-28-6-14715) 2023; 13 Yu (key20241112101859_b22-ol-28-6-14715) 2013; 56 Li (key20241112101859_b77-ol-28-6-14715) 2014; 24 Tang (key20241112101859_b71-ol-28-6-14715) 2013; 33 Feng (key20241112101859_b49-ol-28-6-14715) 2020; 11 Duan (key20241112101859_b39-ol-28-6-14715) 2019; 30 Hooijmans (key20241112101859_b57-ol-28-6-14715) 2014; 14 Wei (key20241112101859_b13-ol-28-6-14715) 2012; 28 Sung (key20241112101859_b3-ol-28-6-14715) 2021; 71 Liu (key20241112101859_b16-ol-28-6-14715) 2005; 100 Potočnjak (key20241112101859_b27-ol-28-6-14715) 2022; 363 Li (key20241112101859_b34-ol-28-6-14715) 2015; 9 Baer-Dubowska (key20241112101859_b15-ol-28-6-14715) 2021; 26 Wang (key20241112101859_b7-ol-28-6-14715) 2019; 2 Alqahtani (key20241112101859_b20-ol-28-6-14715) 2013; 20 Liu (key20241112101859_b50-ol-28-6-14715) 2017; 517 Liu (key20241112101859_b67-ol-28-6-14715) 1993; 266 Bednarczyk-Cwynar (key20241112101859_b48-ol-28-6-14715) 2016; 7 Li (key20241112101859_b52-ol-28-6-14715) 2016; 13 Russo (key20241112101859_b1-ol-28-6-14715) 2019; 305 Liu (key20241112101859_b32-ol-28-6-14715) 2014; 62 Guo (key20241112101859_b37-ol-28-6-14715) 2017; 85 de Oliveira (key20241112101859_b79-ol-28-6-14715) 2022; 36 Page (key20241112101859_b55-ol-28-6-14715) 2021; 372 Zhao (key20241112101859_b25-ol-28-6-14715) 2015; 400 Teodoro (key20241112101859_b21-ol-28-6-14715) 2008; 582 Singh (key20241112101859_b18-ol-28-6-14715) 1992; 44 Bishayee (key20241112101859_b11-ol-28-6-14715) 2016 Zhou (key20241112101859_b84-ol-28-6-14715) 2022; 14 Tang (key20241112101859_b61-ol-28-6-14715) 2013; 24 Pádua (key20241112101859_b19-ol-28-6-14715) 2014; 37 Singh (key20241112101859_b81-ol-28-6-14715) 2022; 176 Kim (key20241112101859_b40-ol-28-6-14715) 2018; 9 Higgins (key20241112101859_b58-ol-28-6-14715) 2021 Wang (key20241112101859_b30-ol-28-6-14715) 2013; 34 Newman (key20241112101859_b10-ol-28-6-14715) 2016; 79 Jiang (key20241112101859_b53-ol-28-6-14715) 2021; 545 Li (key20241112101859_b51-ol-28-6-14715) 2015; 47 Lu (key20241112101859_b76-ol-28-6-14715) 2018; 93 Akter (key20241112101859_b12-ol-28-6-14715) 2021; 22 Sultana (key20241112101859_b14-ol-28-6-14715) 2008; 23 Cao (key20241112101859_b59-ol-28-6-14715) 2021; 10 Prasad (key20241112101859_b17-ol-28-6-14715) 2007; 51 Martín (key20241112101859_b24-ol-28-6-14715) 2010; 79 Wei (key20241112101859_b31-ol-28-6-14715) 2013; 33 Liang (key20241112101859_b46-ol-28-6-14715) 2021; 13 Wang (key20241112101859_b47-ol-28-6-14715) 2019; 18 Zeng (key20241112101859_b42-ol-28-6-14715) 2022; 2022 Yuan (key20241112101859_b2-ol-28-6-14715) 2017; 1401 Gao (key20241112101859_b73-ol-28-6-14715) 2017; 12 Feng (key20241112101859_b78-ol-28-6-14715) 2018; 146 |
| References_xml | – volume: 24 start-page: 405 year: 2022 ident: key20241112101859_b80-ol-28-6-14715 article-title: Use of CRISPR/Cas9 gene editing to improve chimeric antigen-receptor T cell therapy: A systematic review and meta-analysis of preclinical studies publication-title: Cytotherapy doi: 10.1016/j.jcyt.2021.10.010 – volume: 56 start-page: 4300 year: 2013 ident: key20241112101859_b22-ol-28-6-14715 article-title: Development of oleanane-type triterpenes as a new class of HCV entry inhibitors publication-title: J Med Chem doi: 10.1021/jm301910a – volume: 33 start-page: 756 year: 2013 ident: key20241112101859_b31-ol-28-6-14715 article-title: Oleanolic acid arrests cell cycle and induces apoptosis via ROS-mediated mitochondrial depolarization and lysosomal membrane permeabilization in human pancreatic cancer cells publication-title: J Appl Toxicol doi: 10.1002/jat.2725 – volume: 13 start-page: 5276 year: 2016 ident: key20241112101859_b52-ol-28-6-14715 article-title: Oleanolic acid inhibits colorectal cancer angiogenesis in vivo and in vitro via suppression of STAT3 and Hedgehog pathways publication-title: Mol Med Rep doi: 10.3892/mmr.2016.5171 – volume: 44 start-page: 456 year: 1992 ident: key20241112101859_b18-ol-28-6-14715 article-title: Anti-inflammatory activity of oleanolic acid in rats and mice publication-title: J Pharm Pharmacol doi: 10.1111/j.2042-7158.1992.tb03646.x – volume: 40 start-page: 770 year: 2016 ident: key20241112101859_b66-ol-28-6-14715 article-title: Oleanolic acid induces autophagic death in human gastric cancer cells in vitro and in vivo publication-title: Cell Biol Int doi: 10.1002/cbin.10612 – volume: 19 start-page: e2205531 year: 2023 ident: key20241112101859_b83-ol-28-6-14715 article-title: Inherent capability of self-assembling nanostructures in specific proteasome activation for cancer cell pyroptosis publication-title: Small doi: 10.1002/smll.202205531 – volume: 35 start-page: e22621 year: 2021 ident: key20241112101859_b41-ol-28-6-14715 article-title: Inhibition of NF-κB is required for oleanolic acid to downregulate PD-L1 by promoting DNA demethylation in gastric cancer cells publication-title: J Biochem Mol Toxicol doi: 10.1002/jbt.22621 – volume: 11 start-page: 46 year: 2022 ident: key20241112101859_b9-ol-28-6-14715 article-title: Lipids in cancer: A global view of the contribution of lipid pathways to metastatic formation and treatment resistance publication-title: Oncogenesis doi: 10.1038/s41389-022-00420-8 – volume: 18 start-page: 643 year: 2017 ident: key20241112101859_b68-ol-28-6-14715 article-title: Oleanolic acid alters multiple cell signaling pathways: implication in cancer prevention and therapy publication-title: Int J Mol Sci doi: 10.3390/ijms18030643 – volume: 1401 start-page: 19 year: 2017 ident: key20241112101859_b2-ol-28-6-14715 article-title: Natural products to prevent drug resistance in cancer chemotherapy: A review publication-title: Ann N Y Acad Sci doi: 10.1111/nyas.13387 – volume: 37 start-page: 7599 year: 2016 ident: key20241112101859_b35-ol-28-6-14715 article-title: Oleanolic acid inhibits cell survival and proliferation of prostate cancer cells in vitro and in vivo through the PI3K/Akt pathway publication-title: Tumour Biol doi: 10.1007/s13277-015-4655-9 – volume: 15 year: 2016 ident: key20241112101859_b64-ol-28-6-14715 article-title: Inhibitory effect of ursolic acid and oleanolic acid from Eriobotrya fragrans on A549 cell viability in vivo publication-title: Genet Mol Res doi: 10.4238/gmr.15028642 – volume: 14 start-page: 1108 year: 2022 ident: key20241112101859_b75-ol-28-6-14715 article-title: Reparative efficacy of liposome-encapsulated oleanolic acid against liver inflammation induced by fine ambient particulate matter and alcohol in mice publication-title: Pharmaceutics doi: 10.3390/pharmaceutics14051108 – volume: 15 start-page: 4519 year: 2014 ident: key20241112101859_b33-ol-28-6-14715 article-title: p38 MAPK signaling mediates mitochondrial apoptosis in cancer cells induced by oleanolic acid publication-title: Asian Pac J Cancer Prev doi: 10.7314/APJCP.2014.15.11.4519 – volume: 347 start-page: 109619 year: 2021 ident: key20241112101859_b65-ol-28-6-14715 article-title: Anticancer effects of oleanolic acid on human melanoma cells publication-title: Chem Biol Interact doi: 10.1016/j.cbi.2021.109619 – volume: 47 start-page: 2247 year: 2015 ident: key20241112101859_b51-ol-28-6-14715 article-title: Oleanolic acid modulates multiple intracellular targets to inhibit colorectal cancer growth publication-title: Int J Oncol doi: 10.3892/ijo.2015.3198 – volume: 8 start-page: 2917 year: 2013 ident: key20241112101859_b70-ol-28-6-14715 article-title: Self-microemulsifying drug delivery system for improved oral bioavailability of oleanolic acid: Design and evaluation publication-title: Int J Nanomedicine – volume: 146 start-page: 25 year: 2018 ident: key20241112101859_b78-ol-28-6-14715 article-title: PTP1B inhibitory and cytotoxic C-24 epimers of Δ28−24-hydroxy stigmastane-type steroids from the brown alga Dictyopteris undulata Holmes publication-title: Phytochemistry doi: 10.1016/j.phytochem.2017.11.013 – volume: 176 start-page: 103751 year: 2022 ident: key20241112101859_b81-ol-28-6-14715 article-title: Apigenin in cancer prevention and therapy: A systematic review and meta-analysis of animal models publication-title: Crit Rev Oncol Hematol doi: 10.1016/j.critrevonc.2022.103751 – volume: 517 start-page: 1 year: 2017 ident: key20241112101859_b50-ol-28-6-14715 article-title: Preparation, characterization and in vivo pharmacokinetic study of PVP-modified oleanolic acid liposomes publication-title: Int J Pharm doi: 10.1016/j.ijpharm.2016.11.056 – volume: 13 start-page: 337 year: 2023 ident: key20241112101859_b5-ol-28-6-14715 article-title: Hot spots and trends in the relationship between cancer and obesity: A systematic review and knowledge graph analysis publication-title: Life (Basel) – volume: 87 start-page: 104854 year: 2021 ident: key20241112101859_b63-ol-28-6-14715 article-title: Oleanolic acid induces apoptosis and autophagy via the PI3K/AKT/mTOR pathway in AGS human gastric cancer cells publication-title: J Funct Foods doi: 10.1016/j.jff.2021.104854 – volume: 20 start-page: 3849 year: 2019 ident: key20241112101859_b4-ol-28-6-14715 article-title: The expression profile and prognostic significance of metallothionein genes in colorectal cancer publication-title: Int J Mol Sci doi: 10.3390/ijms20163849 – volume: 545 start-page: 81 year: 2021 ident: key20241112101859_b53-ol-28-6-14715 article-title: Oleanolic acid inhibits cervical cancer Hela cell proliferation through modulation of the ACSL4 ferroptosis signaling pathway publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2021.01.028 – volume: 14 start-page: 2938 year: 2022 ident: key20241112101859_b84-ol-28-6-14715 article-title: Comprehensive landscape of RRM2 with immune infiltration in pan-cancer publication-title: Cancers (Basel) doi: 10.3390/cancers14122938 – volume: 85 start-page: 733 year: 2017 ident: key20241112101859_b37-ol-28-6-14715 article-title: NOX2-ROS-HIF-1α signaling is critical for the inhibitory effect of oleanolic acid on rectal cancer cell proliferation publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2016.11.091 – volume: 79 start-page: 629 year: 2016 ident: key20241112101859_b10-ol-28-6-14715 article-title: Natural products as sources of new drugs from 1981 to 2014 publication-title: J Nat Prod doi: 10.1021/acs.jnatprod.5b01055 – start-page: 401 year: 2016 ident: key20241112101859_b11-ol-28-6-14715 article-title: Bioactive natural products in cancer prevention and therapy: Progress and promise publication-title: Semin Cancer Biol – volume: 24 start-page: 235102 year: 2013 ident: key20241112101859_b61-ol-28-6-14715 article-title: An evaluation of the anti-tumor efficacy of oleanolic acid-loaded PEGylated liposomes publication-title: Nanotechnology doi: 10.1088/0957-4484/24/23/235102 – volume: 164 start-page: 706 year: 2019 ident: key20241112101859_b69-ol-28-6-14715 article-title: Synthesis and biological evaluation of novel oleanolic acid analogues as potential α-glucosidase inhibitors publication-title: Eur J Med Chem doi: 10.1016/j.ejmech.2018.12.046 – volume: 363 start-page: 110010 year: 2022 ident: key20241112101859_b27-ol-28-6-14715 article-title: Oleanolic acid induces HCT116 colon cancer cell death through the p38/FOXO3a/Sirt6 pathway publication-title: Chem Biol Interact doi: 10.1016/j.cbi.2022.110010 – volume: 9 start-page: 3017 year: 2015 ident: key20241112101859_b34-ol-28-6-14715 article-title: Oleanolic acid induces mitochondrial-dependent apoptosis and G0/G1 phase arrest in gallbladder cancer cells publication-title: Drug Des Devel Ther doi: 10.2147/DDDT.S84448 – volume: 23 start-page: 739 year: 2008 ident: key20241112101859_b14-ol-28-6-14715 article-title: Oleanolic acid and related derivatives as medicinally important compounds publication-title: J Enzyme Inhib Med Chem doi: 10.1080/14756360701633187 – volume: 100 start-page: 92 year: 2005 ident: key20241112101859_b16-ol-28-6-14715 article-title: Oleanolic acid and ursolic acid: Research perspectives publication-title: J Ethnopharmacol doi: 10.1016/j.jep.2005.05.024 – volume: 8 start-page: e72079 year: 2013 ident: key20241112101859_b29-ol-28-6-14715 article-title: Oleanolic acid suppresses migration and invasion of malignant glioma cells by inactivating MAPK/ERK signaling pathway publication-title: PLoS One doi: 10.1371/journal.pone.0072079 – volume: 12 start-page: 66 year: 2017 ident: key20241112101859_b73-ol-28-6-14715 article-title: Application of hot melt extrusion to enhance the dissolution and oral bioavailability of oleanolic acid publication-title: Asian J Pharm Sci doi: 10.1016/j.ajps.2016.06.006 – volume: 8 start-page: 13864 year: 2015 ident: key20241112101859_b26-ol-28-6-14715 article-title: Oleanolic acid suppresses the proliferation of human bladder cancer by Akt/mTOR/S6K and ERK1/2 signaling publication-title: Int J Clin Exp Pathol – volume: 93 start-page: 63 year: 2018 ident: key20241112101859_b76-ol-28-6-14715 article-title: Identification of an oleanane-type triterpene hedragonic acid as a novel farnesoid X receptor ligand with liver protective effects and anti-inflammatory activity publication-title: Mol Pharmacol doi: 10.1124/mol.117.109900 – volume: 20 start-page: 908 year: 2013 ident: key20241112101859_b20-ol-28-6-14715 article-title: The pentacyclic triterpenoids in herbal medicines and their pharmacological activities in diabetes and diabetic complications publication-title: Curr Med Chem doi: 10.2174/092986713805219082 – volume: 57 start-page: 896 year: 2018 ident: key20241112101859_b36-ol-28-6-14715 article-title: Oleanolic acid induces osteosarcoma cell apoptosis by inhibition of Notch signaling publication-title: Mol Carcinog doi: 10.1002/mc.22810 – volume: 123 start-page: A12 year: 1995 ident: key20241112101859_b56-ol-28-6-14715 article-title: The well-built clinical question: A key to evidence-based decisions publication-title: ACP J Club doi: 10.7326/ACPJC-1995-123-3-A12 – volume: 582 start-page: 1375 year: 2008 ident: key20241112101859_b21-ol-28-6-14715 article-title: Oleanolic acid enhances insulin secretion in pancreatic beta-cells publication-title: FEBS Lett doi: 10.1016/j.febslet.2008.03.026 – volume: 11 start-page: 747 year: 2020 ident: key20241112101859_b49-ol-28-6-14715 article-title: LC-MS-based metabolomic study of oleanolic acid-induced hepatotoxicity in mice publication-title: Front Pharmacol doi: 10.3389/fphar.2020.00747 – volume: 51 start-page: 352 year: 2007 ident: key20241112101859_b17-ol-28-6-14715 article-title: Hepatoprotective effects of lupeol and mango pulp extract of carcinogen induced alteration in Swiss albino mice publication-title: Mol Nutr Food Res doi: 10.1002/mnfr.200600113 – volume: 62 start-page: 5528 year: 2014 ident: key20241112101859_b32-ol-28-6-14715 article-title: Oleanolic acid induces metabolic adaptation in cancer cells by activating the AMP-activated protein kinase pathway publication-title: J Agric Food Chem doi: 10.1021/jf500622p – volume: 7 start-page: 202 year: 2016 ident: key20241112101859_b48-ol-28-6-14715 article-title: Strong and long-lasting antinociceptive and anti-inflammatory conjugate of naturally occurring oleanolic acid and aspirin publication-title: Front Pharmacol doi: 10.3389/fphar.2016.00202 – volume: 19 start-page: 199 year: 2024 ident: key20241112101859_b43-ol-28-6-14715 article-title: A synergistic combination of oleanolic acid and apatinib to enhance antitumor effect on liver cancer cells and protect against hepatic injury publication-title: Recent Pat Anticancer Drug Discov doi: 10.2174/1574892818666230417093208 – volume: 221 start-page: 92 year: 2014 ident: key20241112101859_b60-ol-28-6-14715 article-title: Meta-analysis of data from animal studies: a practical guide publication-title: J Neurosci Methods doi: 10.1016/j.jneumeth.2013.09.010 – volume: 24 start-page: 90 year: 2004 ident: key20241112101859_b23-ol-28-6-14715 article-title: Chemistry, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer and HIV infection publication-title: Med Res Rev doi: 10.1002/med.10053 – volume: 99 start-page: 65 year: 2016 ident: key20241112101859_b72-ol-28-6-14715 article-title: Dual strategies to improve oral bioavailability of oleanolic acid: Enhancing water-solubility, permeability and inhibiting cytochrome P450 isozymes publication-title: Eur J Pharm Biopharm doi: 10.1016/j.ejpb.2015.11.013 – volume: 26 start-page: 4957 year: 2021 ident: key20241112101859_b15-ol-28-6-14715 article-title: Anti-cancer potential of synthetic oleanolic acid derivatives and their conjugates with NSAIDs publication-title: Molecules doi: 10.3390/molecules26164957 – volume: 28 start-page: 1339 year: 2012 ident: key20241112101859_b13-ol-28-6-14715 article-title: Oleanolic acid potentiates the antitumor activity of 5-fluorouracil in pancreatic cancer cells publication-title: Oncol Rep doi: 10.3892/or.2012.1921 – volume: 372 start-page: n160 year: 2021 ident: key20241112101859_b55-ol-28-6-14715 article-title: PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews publication-title: BMJ doi: 10.1136/bmj.n160 – volume: 24 start-page: 4125 year: 2014 ident: key20241112101859_b77-ol-28-6-14715 article-title: Synthesis and biological evaluation of novel thiadiazole amides as potent Cdc25B and PTP1B inhibitors publication-title: Bioorg Med Chem Lett doi: 10.1016/j.bmcl.2014.07.055 – volume: 2 start-page: 141 year: 2019 ident: key20241112101859_b7-ol-28-6-14715 article-title: Drug resistance and combating drug resistance in cancer publication-title: Cancer Drug Resist – volume: 14 start-page: 43 year: 2014 ident: key20241112101859_b57-ol-28-6-14715 article-title: SYRCLE's risk of bias tool for animal studies publication-title: BMC Med Res Methodol doi: 10.1186/1471-2288-14-43 – volume: 10 start-page: 5390 year: 2021 ident: key20241112101859_b59-ol-28-6-14715 article-title: Antitumor activity of fucoidan: A systematic review and meta-analysis publication-title: Transl Cancer Res doi: 10.21037/tcr-21-1733 – volume: 22 start-page: 4180 year: 2021 ident: key20241112101859_b12-ol-28-6-14715 article-title: A comprehensive analysis into the therapeutic application of natural products as SIRT6 modulators in alzheimer's disease, aging, cancer, inflammation, and diabetes publication-title: Int J Mol Sci doi: 10.3390/ijms22084180 – volume: 712 start-page: 143956 year: 2019 ident: key20241112101859_b38-ol-28-6-14715 article-title: Oleanolic acid reduces aerobic glycolysis-associated proliferation by inhibiting yes-associated protein in gastric cancer cells publication-title: Gene doi: 10.1016/j.gene.2019.143956 – volume: 33 start-page: 46 year: 2013 ident: key20241112101859_b71-ol-28-6-14715 article-title: Advances in the study of structural modification and biological activities of oleanolic acid publication-title: Chin J Org Chem doi: 10.6023/cjoc201207019 – volume: 13 start-page: 22883 year: 2021 ident: key20241112101859_b46-ol-28-6-14715 article-title: Transcriptome study of oleanolic acid in the inhibition of breast tumor growth based on high-throughput sequencing publication-title: Aging (Albany NY) doi: 10.18632/aging.203582 – volume: 8 start-page: 35 year: 2020 ident: key20241112101859_b82-ol-28-6-14715 article-title: Resistance to PD-1/PD-L1 blockade cancer immunotherapy: Mechanisms, predictive factors, and future perspectives publication-title: Biomark Res doi: 10.1186/s40364-020-00212-5 – volume: 400 start-page: 1 year: 2015 ident: key20241112101859_b25-ol-28-6-14715 article-title: Oleanolic acid suppresses the proliferation of lung carcinoma cells by miR-122/Cyclin G1/MEF2D axis publication-title: Mol Cell Biochem doi: 10.1007/s11010-014-2228-7 – volume: 9 start-page: 26370 year: 2018 ident: key20241112101859_b40-ol-28-6-14715 article-title: Oleanolic acid induces p53-dependent apoptosis via the ERK/JNK/AKT pathway in cancer cell lines in prostatic cancer xenografts in mice publication-title: Oncotarget doi: 10.18632/oncotarget.25316 – volume: 71 start-page: 209 year: 2021 ident: key20241112101859_b3-ol-28-6-14715 article-title: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries publication-title: CA Cancer J Clin doi: 10.3322/caac.21660 – year: 2021 ident: key20241112101859_b58-ol-28-6-14715 article-title: Cochrane handbook for systematic reviews of interventions version 6.2 [updated February 2021] publication-title: Cochrane – volume: 9 start-page: 193 year: 2012 ident: key20241112101859_b6-ol-28-6-14715 article-title: Cancer and radiation therapy: Current advances and future directions publication-title: Int J Med Sci doi: 10.7150/ijms.3635 – volume: 18 start-page: 583 year: 2018 ident: key20241112101859_b62-ol-28-6-14715 article-title: Oleanolic acid inhibits colorectal cancer angiogenesis by blocking the VEGFR2 signaling pathway publication-title: Anticancer Agents Med Chem doi: 10.2174/1871520617666171020124916 – volume: 37 start-page: 1487 year: 2014 ident: key20241112101859_b19-ol-28-6-14715 article-title: Anti-inflammatory effects of methyl ursolate obtained from a chemically derived crude extract of apple peels: Potential use in rheumatoid arthritis publication-title: Arch Pharm Res doi: 10.1007/s12272-014-0345-1 – volume: 11 start-page: 1417 year: 2017 ident: key20241112101859_b74-ol-28-6-14715 article-title: Preparation, characterization, and in vitro/vivo studies of oleanolic acid-loaded lactoferrin nanoparticles publication-title: Drug Des Devel Ther doi: 10.2147/DDDT.S133997 – volume: 73 start-page: 968 year: 2021 ident: key20241112101859_b44-ol-28-6-14715 article-title: Oleanolic acid suppressed DMBA-induced liver carcinogenesis through induction of mitochondrial-mediated apoptosis and autophagy publication-title: Nutr Cancer doi: 10.1080/01635581.2020.1776887 – volume: 266 start-page: 1607 year: 1993 ident: key20241112101859_b67-ol-28-6-14715 article-title: Protective effects of oleanolic acid on acetaminophen-induced hepatotoxicity in mice publication-title: J Pharmacol Exp Ther – volume: 29 start-page: 846 year: 2011 ident: key20241112101859_b28-ol-28-6-14715 article-title: Inhibition of mTOR signaling by oleanolic acid contributes to its anti-tumor activity in osteosarcoma cells publication-title: J Orthop Res doi: 10.1002/jor.21311 – volume: 372 start-page: n71 year: 2021 ident: key20241112101859_b54-ol-28-6-14715 article-title: The PRISMA 2020 statement: An updated guideline for reporting systematic reviews publication-title: BMJ doi: 10.1136/bmj.n71 – volume: 2022 start-page: 5887671 year: 2022 ident: key20241112101859_b42-ol-28-6-14715 article-title: Oleanolic acid (OA) targeting UNC5B inhibits proliferation and EMT of ovarian cancer cell and increases chemotherapy sensitivity of niraparib publication-title: J Oncol doi: 10.1155/2022/5887671 – volume: 30 start-page: 812 year: 2019 ident: key20241112101859_b39-ol-28-6-14715 article-title: Oleanolic acid inhibits cell proliferation migration and invasion and induces SW579 thyroid cancer cell line apoptosis by targeting forkhead transcription factor A publication-title: Anticancer Drugs doi: 10.1097/CAD.0000000000000777 – volume: 36 start-page: 3202 year: 2022 ident: key20241112101859_b79-ol-28-6-14715 article-title: Preclinical studies of the antitumor effect of curcumin-loaded polymeric nanocapsules: A systematic review and meta-analysis publication-title: Phytother Res doi: 10.1002/ptr.7538 – volume: 18 start-page: 62 year: 2019 ident: key20241112101859_b47-ol-28-6-14715 article-title: Oleanolic acid inhibits epithelial-mesenchymal transition of hepatocellular carcinoma by promoting iNOS dimerization publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-18-0448 – volume: 34 start-page: 1323 year: 2013 ident: key20241112101859_b30-ol-28-6-14715 article-title: Inhibitory effect of oleanolic acid on hepatocellular carcinoma via ERK-p53-mediated cell cycle arrest and mitochondrial-dependent apoptosis publication-title: Carcinogenesis doi: 10.1093/carcin/bgt058 – volume: 305 start-page: 79 year: 2019 ident: key20241112101859_b1-ol-28-6-14715 article-title: Antigrowth activity and induction of apoptosis in human melanoma cells by Drymis winteri forst extract and its active components publication-title: Chem Biol Interact doi: 10.1016/j.cbi.2019.03.029 – volume: 22 start-page: 9451 year: 2021 ident: key20241112101859_b8-ol-28-6-14715 article-title: Battling chemoresistance in cancer: Root causes and strategies to uproot them publication-title: Int J Mol Sci doi: 10.3390/ijms22179451 – volume: 145 start-page: 112397 year: 2022 ident: key20241112101859_b45-ol-28-6-14715 article-title: Anticancer activity of oleanolic acid and its derivatives: Recent advances in evidence, target profiling and mechanisms of action publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2021.112397 – volume: 79 start-page: 198 year: 2010 ident: key20241112101859_b24-ol-28-6-14715 article-title: Beneficial actions of oleanolic acid in an experimental model of multiple sclerosis: A potential therapeutic role publication-title: Biochem Pharmacol doi: 10.1016/j.bcp.2009.08.002 |
| SSID | ssj0000561886 |
| Score | 2.3433945 |
| Snippet | Oleanolic acid (OA), a compound known for its potent antitumour properties, has been the subject of investigations in both cell and animal models. Although OA... |
| SourceID | pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Access Repository Aggregation Database Index Database |
| StartPage | 582 |
| SubjectTerms | Acids Animal research Bias Bioavailability Cancer Cancer therapies Care and treatment Cell cycle Drug dosages Drug resistance Intervention Laboratory animals Meta-analysis Mortality Natural products Radiation Software Systematic review Tumors |
| Title | Antitumour activity of oleanolic acid: A systematic review and meta‑analysis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/39421313 https://www.proquest.com/docview/3126840613 https://pubmed.ncbi.nlm.nih.gov/PMC11484195 |
| Volume | 28 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NTtwwEB5RkKpeKvq_lFIfKjhZZB0nTrhUWwRCSLtCVZH2Zjn2REWiCYXlziv0FfsknUm8y6YHjomtxJrx_Nkz3wB8yZKqTsiMyCJTmSR7XMtClSgx6OC0rl2ecDXydJafXerzeTaPB253Ma1yqRM7RR1az2fkh-m4wyUh6_P15rfkrlF8uxpbaDyDLYYu45QuMzerMxb2jouu2SNtOyU597CH2SQrrQ5bvnlQmnSF4aa4a2bpf-W8Zp2GmZNrpuh0G15GH1JMeqa_gg1sXsPzabwlfwOzCdfe3lNQfyu4boHbQ4i2Fu01uoZxgOntVTgSE_GI4yz6GhbhmiB-4cL9ffjjIl7JW7g8PflxfCZj3wTptUkWMkVHQUiK4yQJuaqwrEufJjj2Nfk7ZH2qvHS6NF75ssYipCFTxhhXOV1kiGTT3sFm0zb4AQQFbwEpKCtYbhHzkjykOiEWkh_mHVYj2F-Szd708BiWwgqmr22vLdPXdvQdwWcmqu2rO1diZSf0ZZOzqhvBQTeDBYto612sD6CFMETVYObuYCYJhB8OLxlno0De2cftM4L3PQ9XC05LrcYpjxQD7q4mMAT3cKS5-tlBcXM0qWnn7Tz9z4_wgknRp8Hswubi9h4_kTOzqPa6HbsHW99OZhff6Wl2Mf0Hapf1Lg |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VrQRcUHkvFOoDj1PUxHEeRqrQAq22tLtCqJV6cx1nIiq1SR9bIW78Bf5If1R_CTN5bDccuPUajxxrZjwP2_MNwJvIzwqf3IiXRjLyyB8XXio1epir3CpV2NjnauTJNB7vq68H0cESXHW1MPyssrOJtaHOK8dn5OthUOOSkPf5eHrmcdcovl3tWmg0arGDv35Synaxsf2F5PtWyq3Nvc9jr-0q4DmV-DMvREsheoiB7-exzFAX2oU-Bq6gaIBscxZrq3TipNMFpnmYRzJJEptZlUaIZPFp3juwrEJKZQaw_Glz-u37_FSH4_G0bi9Jii49fu3YAHtSXCDXK77rkIqsU8JteBcc4b_uYMEf9t9qLji_rRV40EatYtSo2UNYwvIR3J209_KPYTriat_LE6ITXCnBDSlEVYjqGG3JyMP09Sj_IEbiBjlaNFUzwpa5OMGZvf79x7YIKU9g_1Z4-hQGZVXicxCULuZIaWDKlgIx1hSTFT4pDUV-zmI2hHcd28xpA8hhKJFh_prq2DB_Tc3fIawxU01TTzrfyGZEMycxG9chvK8peCsTb51tKxJoIQyK1aNc7VHSFnT94U5wpjUBF-ZGYYfwrJHhfMGhVjIIeSTtSXdOwKDf_ZHy6EcN_s35qwp09OL__1yDe-O9ya7Z3Z7uvIT7zJbmEc4qDGbnl_iKQqlZ9rrVXwGHt71l_gISfTCq |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIlVcEG8WSusDj1O0iePECRKqVi2rltIVByrtzTj2RFRqk0K3Qtz4C_wdfg6_pDN5bDccuPUaj5xoPM945huAl0lYlCG5kSBLZBKQPy6DTOYYoFfeKlXaNORu5KNZun-sPsyT-Rr86XthuKyyt4mNofa143_k4zhqcEnI-4zLrizi09505_xbwBOk-Ka1H6fRisgh_vxB6dvFu4M9OutXUk7ff97dD7oJA4FTOlwEMVoK12OMwtCnssC8zF0cYuRKigzIThdpblWunXR5iZmPfSK11rawKksQyfrTvrfgto6TiHVMz_Xy_w5H5lkzaJJEXgZc99hCfFKEIMc133pIRXZK80DeFZf4r2NY8YzDqs0VNzi9B3e7-FVMWoG7D2tYPYCNo-6G_iHMJtz3e3lGdIJ7Jng0hahLUZ-irRiDmJ6e-LdiIq4xpEXbPyNs5cUZLuzfX79th5XyCI5vhKOPYb2qK3wKghJHj5QQZmwzENOcorMyJPGhGNBZLEbwumebOW-hOQylNMxfU58a5q9p-DuCbWaqaTtLlyptJrSzTtnMjuBNQ8FKTbx1tutNoA9heKwB5eaAkpTRDZf7gzOdMbgw16I7giftGS4_OM6VjGJeyQanuyRg-O_hSnXytYEB50xWRXny7P_v3IYNUhTz8WB2-BzuMFfaapxNWF98v8QXFFMtiq1GeAV8uWltuQLvhzN6 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Antitumour+activity+of+oleanolic+acid%3A+A+systematic+review+and+meta%E2%80%91analysis&rft.jtitle=Oncology+letters&rft.au=Zeng%2C+Ying&rft.au=Wang%2C+Zhonglian&rft.au=Zhang%2C+Jing&rft.au=Jian%2C+Wei&rft.date=2024-12-01&rft.issn=1792-1074&rft.eissn=1792-1082&rft.volume=28&rft.issue=6&rft_id=info:doi/10.3892%2Fol.2024.14715&rft.externalDBID=n%2Fa&rft.externalDocID=10_3892_ol_2024_14715 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1792-1074&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1792-1074&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1792-1074&client=summon |